September 4, 2018 (Source) — Scythian Biosciences Corp. (the “Company” or “Scythian”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) announced today that it has appointed Andrew DeFrancesco to the Board of Directors effective September 4, 2018. Mr. DeFrancesco has over 26 years of capital markets experience, from senior positions at some of Canada’s most established independent investment firms in trading, sales and investment banking, to establishing first mover status as the founder and co-founder of a number of North American small and mid-capital companies and sectors.